Editorial Team Getting a promising scientific discovery out of the lab and into the hands of patients is a constant struggle. Biotech startups are supposed to be the ones to bridge that gap with their new ideas and fast-moving teams, but they often get stuck. The world of clinical trials is a maze, and securing enough healthcare funding is an absolute monster of a hurdle. So how can a small company actually use insights from an organization like the World Health Organization (WHO) to make a bigger, faster impact?
Key Takeaways
- The WHO’s International Clinical Trials Registry Platform (ICTRP) is a public database you can use to find active trials, potential partners, and see where the real medical needs are.
- Biotech startups that align their R&D with WHO’s priority diseases and health initiatives have a much better shot at attracting targeted funding.
- Paying attention to the regulatory harmonization work the WHO promotes can seriously simplify plans for multi-country trials and speed up market entry.
- Early-stage funding for clinical trials usually comes down to proving a clear, unmet need and having a solid development plan that lines up with global health goals.
Dr. Anya Sharma, the CEO of Novagen Therapeutics, knew this problem all too well. Her company, a small but scrappy biotech working out of Boston’s Seaport District, had a new gene therapy for a rare pediatric neurological disorder. The preclinical data was great, it showed real promise in animal models. But as 2024 was ending, Novagen was at a standstill, needing to raise a ton of money just to start Phase 1 clinical trials.
Anya knew that attracting big money required more than just exciting science. Investors wanted to see a clear path to market, a defined regulatory strategy, and hard evidence of a global health need. “We had the science,” Anya recalled in a recent interview, “but we needed to show the broader impact, especially for a condition affecting kids all over the world. That’s when we started digging into the WHO’s data.”
The World Health Organization’s programs and data initiatives offer a treasure trove of information that can guide a startup. One of the most practical tools is the International Clinical Trials Registry Platform (ICTRP). This thing pulls together trial registration data from registries all over the world, giving you a full picture of what studies are happening. For Novagen, a search on the ICTRP showed just how few active trials there were for their specific rare disease and, importantly, where they were located. “It showed us where the gaps were,” Anya explained. “Almost all the work was happening in North America and Western Europe, leaving huge populations completely underserved.”
That single insight completely reshaped Novagen’s pitch to investors. They weren’t just presenting a scientific breakthrough anymore. They were framing it in a global context, pointing to the unmet need in regions that current research was ignoring. A 2025 report from the WHO’s Department of Research for Health (DRH) points out that global health research funding tends to flow to diseases common in high-income countries. “Showing you’re aligned with global health equity, even if you’re working on a rare disease, can really get the attention of certain philanthropic funds and impact investors,” confirmed Dr. Elena Petrova, a life sciences VC at BioBridge Ventures over near Kendall Square in Cambridge.
The ICTRP also let Novagen pick apart existing trial designs and endpoints. They weren’t trying to copy anyone, but seeing what the rest of the field was doing helped them sharpen their own protocol to be sure it was both new and, critically, doable. It also pointed them toward potential collaborators at universities and research networks who already had experience with similar patient groups.
WHO’s work on regulatory harmonization was another goldmine. The WHO doesn’t make the rules itself, but it works with national regulators to standardize how drugs are developed and approved, and its guidelines often shape national policy. For a startup like Novagen that was already thinking about multi-country trials, figuring out these trends was essential. “The prospect of running trials across different regulatory frameworks can be daunting for any company, let alone a startup,” Anya admitted. “Knowing that there are ongoing efforts towards greater alignment, even if it’s slow, gave us a clearer long-term strategy.”
Securing healthcare funding for early-stage development is brutally difficult. A 2024 analysis from the National Institutes of Health (NIH) found only about 10% of preclinical drug candidates even make it to Phase 1 trials. Novagen had to stand out. They used the insights they pulled from the WHO to build a story for investors, hitting on not just the science but the global health impact and their smart approach to trial design.
Anya’s team mapped their proposed clinical trial against WHO’s essential medicines list and priority disease areas. Their specific condition wasn’t on the lists, but they argued that the genetic mechanisms and the therapy itself could apply to other rare neurological disorders that *were* on WHO’s radar. That forward-thinking view, along with a detailed breakdown of their Phase 1 protocol, got the attention of the investment committee at Global Health Initiatives (GHI), a foundation known for backing health solutions with global reach.
GHI’s due diligence was intense. They tore apart Novagen’s preclinical data, grilled the team on their expertise, and picked over their clinical trial design. But Novagen had an edge. They could clearly articulate how their work fit into global health priorities, and they had the data from the ICTRP and WHO reports on disease burden to prove it. It showed a kind of strategic depth that’s often missing from early-stage biotech pitches. “It showed us they weren’t just thinking about the science,” said Dr. Kenji Tanaka, a senior investment partner at GHI. “They were thinking about the patient, the global need, and the pathway to impact.”
In mid-2025, Novagen Therapeutics successfully closed its Series A round, bringing in $30 million. A huge chunk of that was set aside for their Phase 1 clinical trial. The money let them finalize their investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) and start recruiting patients at specialized centers like Boston Children’s Hospital and the Children’s Hospital of Philadelphia. The path from a lab discovery to a clinical reality is long and full of traps, but for Novagen, the insights they pulled from WHO’s data acted as a much-needed compass.
Biotech startups, especially those in niche or rare disease spaces, have to look past the immediate scientific problems. They have to understand the entire global health picture. By digging into resources like the ICTRP, keeping an eye on WHO publications, and putting their work into a global context, these companies can make themselves far more attractive to investors and get their therapies to patients faster. Good science alone doesn’t cut it.
For Novagen, that first round of funding was just the beginning. The road ahead is all about managing complex trial logistics, tracking patient outcomes, and prepping for the next phases. But their strategic use of WHO data built a strong foundation, proving that even the smallest biotech startup can get a huge leg up from a global perspective when trying to turn a discovery into a real-world patient benefit.
Getting through the jungle of clinical trials and securing healthcare funding takes more than just scientific talent. It takes a strategic grasp of global health priorities and regulatory systems. The biotech startups that build WHO insights into their development plans from the start will be in a much stronger position to get the investment they need and bring their therapies to patients around the world.
What is the WHO’s International Clinical Trials Registry Platform (ICTRP)?
The ICTRP is a free, public portal from the World Health Organization that centralizes clinical trial registration data from all over the world. Its purpose is to make information about ongoing and completed clinical research transparent and accessible.
How can biotech startups use ICTRP data to their advantage?
Startups use the ICTRP to spot research gaps, size up the competition for specific diseases, analyze the trial designs of other studies, and even find potential collaborators or patient recruitment sites in different countries.
Does the WHO provide direct funding for biotech startups?
No, the WHO doesn’t typically write checks to commercial biotech startups. Its job is to set global health standards and coordinate international health work. But, aligning your work with WHO’s priorities can make your company much more attractive to other funders, like philanthropic groups and impact investors.
How do WHO guidelines influence national regulatory bodies for clinical trials?
The WHO isn’t a regulator, but its guidelines on good clinical practice, ethics, and essential medicines are often used as the benchmark by national agencies. Following these international standards can make it easier to get regulatory approval and market access in different countries.
What role do WHO’s priority disease lists play in attracting healthcare funding?
WHO’s priority lists point to diseases with a major global health burden or unmet need. If your startup is developing a treatment for one of those conditions, you may find it’s easier to get funding from governments, NGOs, and foundations that focus on solving those specific health problems.
